Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Alligator Bioscience

0,42 SEK

+8,85 %

Mindre end 1K følgere

ATORX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+8,85 %
-26,62 %
-63,89 %
-63,65 %
-92,91 %
-92,92 %
-98,34 %
-99,53 %
-99,91 %

Alligator Bioscience is a research-based biotechnology company that uses patented technology to develop biological drug candidates in inflammation and cancer. The company is active in the former part of the drug development chain. Alligator Bioscience has a global technology platform and is active in a rapidly growing segment of the pharmaceutical market - protein drugs. The company was founded in 2001 and is headquartered in Lund, Sweden.

Læs mere
Markedsværdi
275,5 mio. SEK
Aktieomsætning
1,11 mio. SEK
Omsætning
57,77 mio.
EBIT %
-396,64 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
12.2
2026

Årsrapport '25

6.5
2026

Generalforsamling '26

Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelsei går

Alligator publishes supplement prospectus

Alligator Bioscience
Selskabsmeddelelsei går

Alligator Bioscience publishes financial calendar for 2026

Alligator Bioscience
Selskabsmeddelelse1.12.2025, 17.30

Alligator Bioscience enters into additional subscription undertakings and top guarantee commitments for the upcoming rights issue

Alligator Bioscience

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse1.12.2025, 07.45

Alligator Bioscience announces publication of REACtiVe-2 Phase 1 trial data in Nature Communications

Alligator Bioscience
Selskabsmeddelelse28.11.2025, 10.45

Alligator Bioscience publishes prospectus in connection with rights issue

Alligator Bioscience
Selskabsmeddelelse25.11.2025, 10.45

Bulletin from the extraordinary general meeting in Alligator Bioscience AB

Alligator Bioscience
Selskabsmeddelelse24.11.2025, 20.00

Alligator Bioscience announces final terms of rights issue

Alligator Bioscience
Pressemeddelelse19.11.2025, 07.13

BioStock: Video from Alligator Bioscience's presentation at BioStock Life Science Summit 2025

Alligator Bioscience
Pressemeddelelse5.11.2025, 10.00

Alligator Bioscience presents new data on mitazalimab and ATOR-4066 at SITC 40th Anniversary Annual Meeting

Alligator Bioscience
Selskabsmeddelelse3.11.2025, 14.00

Nomination Committee appointed in respect of AGM 2026 in Alligator Bioscience AB

Alligator Bioscience
Pressemeddelelse24.10.2025, 07.10

Redeye: Alligator Bioscience (Q3 Review) - Rights Issue of up to SEK120m

Alligator Bioscience
Selskabsmeddelelse23.10.2025, 06.00

Alligator Bioscience AB reports financial results for Q3 2025 and provides a business update

Alligator Bioscience
Selskabsmeddelelse22.10.2025, 21.55

Notice of extraordinary general meeting in Alligator Bioscience AB

Alligator Bioscience
Selskabsmeddelelse22.10.2025, 21.05

Alligator Bioscience carries out a rights issue of units of approximately SEK 120 million and raises bridge loans

Alligator Bioscience
Pressemeddelelse21.10.2025, 08.30

Alligator Bioscience granted US patent covering ATOR-4066 bispecific antibody

Alligator Bioscience
Pressemeddelelse16.10.2025, 06.45

Invitation to Alligator Bioscience's earnings call on 23 October 2025

Alligator Bioscience
Pressemeddelelse13.10.2025, 06.45

REACtiVe-2 Phase 1 data featuring mitazalimab demonstrate immune activation in metastatic pancreatic cancer – to be presented at ESMO 2025

Alligator Bioscience
Pressemeddelelse8.10.2025, 06.45

Alligator announces publication of OPTIMIZE-1 biomarker analysis in Cell Reports Medicine supporting mitazalimab and mFOLFIRINOX in metastatic pancreatic cancer

Alligator Bioscience
Pressemeddelelse6.10.2025, 13.00

Alligator Bioscience announces acceptance of two abstracts at SITC 40th Anniversary Annual Meeting

Alligator Bioscience
Selskabsmeddelelse30.9.2025, 13.00

Change in number of shares and votes in Alligator Bioscience AB

Alligator Bioscience
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.